Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Chalcis – page 2

159 clinical trials in Chalcis, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Chalcis at a glance
159
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

159 trials in Chalcis

Open in trial search

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Study of Elafibranor for Adults with Primary Biliary Cholangitis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

Cardiac failure

Recruiting

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center

Breast cancer

Recruiting

Study of Tersolisib and a drug combination for adults with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Glaxosmithkline Research & Development Limited

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG

A study of MK-1084 and pembrolizumab for patients with resected KRAS G12C-mutant non-small cell lung cancer

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

A double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Colorectal cancer+2

Recruiting

Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Study of telisotuzumab adizutecan plus drug combination in adults with refractory metastatic colorectal cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Greece

The busiest research cities in the country

All 48 cities in Greece

Clinical research in Chalcis

What the registry says about research in the country

01 Cardiovascular Diseases

Clinical trial activity in Chalkida is focused entirely on cardiovascular diseases, with studies centered on different forms of heart failure. The research is mainly aimed at evaluating new treatment approaches that may help reduce serious heart-related events and improve symptom control.

  • Heart failure with reduced ejection fraction
  • HFpEF and HFmrEF linked to obesity
  • Heart failure with systemic inflammation
  • Testing whether new therapies can improve outcomes beyond standard care

These trials are exploring both treatment effectiveness and the potential to lower risks such as cardiovascular death, hospitalisation, and urgent care visits.

02 Heart Failure Research

Current studies in this area are examining whether targeted therapies can better manage symptomatic heart failure in patients whose condition remains difficult to control. The focus is on improving long-term outcomes for people with more advanced forms of the disease.

  • HFrEF with severely reduced ejection fraction
  • Comparing a new treatment with placebo
  • Assessing added benefit alongside guideline-directed medical therapy

This line of research aims to clarify whether new options can offer meaningful benefit in everyday clinical care.

03 Inflammation and Obesity in Heart Failure

Another important research theme links heart failure with systemic inflammation and obesity, reflecting growing interest in how these factors influence disease progression. The studies are designed to test whether newer therapies can address these overlapping risks more effectively.

  • HFpEF and HFmrEF with obesity
  • Heart failure with inflammation
  • Evaluating whether treatment can reduce major cardiovascular events
  • Supporting better control of complex, mixed-risk patient groups

Together, these trials reflect a focused effort in Greece to improve care for people living with challenging forms of heart failure.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.